So Far We've Raised




Our fundraising supports Oligodendroglioma research. We believe there is a cure and that we can find it. Join our mission and donate today.


OPERATION OLIGO CURE (OOC) was created to fund research and clinical trials for the rare brain tumor- Oligodendrogliomas. Oligodendrogliomas impact thousands of people worldwide.

In the spring of 2015 Operation Oligo Cure donated its first grant to MD Anderson Cancer Center to establish the Operation Oligocure Research Fund.  This premiere cancer research center is currently utilizing the fund to conduct genomic analysis and molecular profiling of resected oligodendroglioma tumors. Our combined goal is to find mutations similar to other more prevalent tumors that have well established effective treatments. These treatments can then be applied to patients with oligodendrogliomas. In addition, funds were used to hire dedicated research fellows to create oligodendroglioma tumor lines in the lab that will allow testing of potential future treatments. These are the building blocks of future cures.
Every dollar raised by OOC goes directly toward research specific to Oligodendroglioma brain tumors.  All administrative costs of the foundation are covered by its Board of Directors.

Brain tumors are the second leading cause of cancer-related deaths in children under age 20

Brain tumors are the second leading cause of cancer-related deaths in males ages 20- 39

Brain tumors are the fifth leading cause of cancer-related deaths in females ages 20- 39

OLIGODENDROGLIOMA (oligo den dro glioma)

Glioma is the name of a group of tumors that arise from the supporting cells in the brain. Oligodendroglioma is a specific type of glioma also known as a brain tumor. They are soft, greyish-pink and frequently occur in the frontal or temporal lobe although, can be found anywhere within the cerebral

hemisphere of the brain. They can be classified as low grade or high grade. They are common among men and women in their 20s-40s, but can occur in children. Oligodendrogliomas represent 4% of all primary brain tumors.